Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/2270
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chen, C.L. | en_US |
dc.contributor.author | Venketasubramanian, N. | en_US |
dc.contributor.author | Lee, C.F. | en_US |
dc.contributor.author | Wong, K.S. | en_US |
dc.contributor.author | Bousser, M.G. | en_US |
dc.contributor.author | CHIMES Study Investigators | en_US |
dc.contributor.author | de Silva, A. with 38 CHIMES Study Investigators | en_US |
dc.date.accessioned | 2014-10-29T09:41:03Z | |
dc.date.available | 2014-10-29T09:41:03Z | |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | Stroke. 2013; 44(12):3580-3.[Epub 2013 Oct 17.] | en_US |
dc.identifier.issn | 0039-2499 (Print) | en_US |
dc.identifier.issn | 1524-4628 (Electronic) | en_US |
dc.identifier.other | 10.1161/STROKEAHA.113.003226 | en |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/2270 | |
dc.description.abstract | BACKGROUND AND PURPOSE: Early vascular events are an important cause of morbidity and mortality in the first 3 months after a stroke. We aimed to investigate the effects of MLC601 on the occurrence of early vascular events within 3 months of stroke onset. METHODS: Post hoc analysis was performed on data from subjects included in the CHInese Medicine Neuroaid Efficacy on Stroke recovery(CHIMES) study, a randomized, placebo-controlled, double-blinded trial that compared MLC601 with placebo in 1099 subjects with ischemic stroke of intermediate severity in the preceding 72 hours. Early vascular events were defined as a composite of recurrent stroke, acute coronary syndrome, and vascular death occurring within 3 months of stroke onset. RESULTS: The frequency of early vascular events during the 3-month follow-up was significantly less in the MLC601 group than in the placebo group (16 [2.9%] versus 31 events [5.6%]; risk difference=-2.7%; 95% confidence interval, -5.1% to -0.4%; P=0.025) without an increase in nonvascular deaths. Kaplan-Meier survival analysis showed a difference in the risk of vascular outcomes between the 2 groups as early as the first month after stroke (Log-rank P=0.024; hazard ratio, 0.51; 95% confidence interval, 0.28-0.93). CONCLUSIONS: Treatment with MLC601 was associated with reduced early vascular events among subjects in the CHIMES study. The mechanisms for this effect require further study. CLINICAL TRIAL REGISTRATION URL://www.clinicaltrials.gov. Unique identifier: NCT00554723. | |
dc.publisher | Lippincott Williams and Wilkins | en_US |
dc.source.uri | http://stroke.ahajournals.org/content/44/12/3580.long | en |
dc.title | Effects of MLC601 on early vascular events in patients after stroke: the CHIMES study | en_US |
dc.type | Article | en_US |
dc.identifier.department | Pharmacology | en_US |
dc.creator.corporateauthor | American Heart Association | en_US |
dc.description.note | Indexed in MEDLINE | en_US |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
chen-2013-stroke-3580.pdf | 424.24 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.